Last reviewed · How we verify
NCT07341230: Brain-PACER
Deep Brain Stimulation to Understand and Treat Addiction
NA trial testing Dual-Target Deep Brain Stimulation in Alcohol Use Disorder in 9 participants. Currently enrolling.
31 October 2027
Quick facts
| Lead sponsor | University of Cambridge |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 9 |
| Start date | 1 July 2025 |
| Primary completion | 31 October 2027 |
| Estimated completion | 31 October 2027 |
| Sites | 2 locations across United Kingdom |
Drugs / interventions tested
- Dual-Target Deep Brain Stimulation
- Nucleus Accumbens Deep Brain Stimulation
- Ventral Internal Capsule Deep Brain Stimulation
- Sham Deep Brain Stimulation
Conditions studied
- Alcohol Use Disorder — all drugs for Alcohol Use Disorder →
Sponsor
University of Cambridge
Who can join
Adults 18 to 60, any sex, with Alcohol Use Disorder. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is testing whether deep brain stimulation (DBS) can safely help people with severe alcohol use disorder who have not improved with standard treatments. DBS uses small electrical signals to change activity in brain areas linked to craving, self-control, and emotion. The study will test whether this treatment can reduce how often people drink and how much they drink each day. Researchers will also record brain activity to better understand how DBS affects craving and relapse.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07341230
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Alcohol Use Disorder
Currently open trials in the same condition.
- NCT06860607 — Environment and Alcohol: A Pilot Study · Phase 1 · recruiting
- NCT07325266 — Human Laboratory Study of Apremilast for Alcohol Use Disorder · Phase 2 · recruiting
- NCT07046819 — Tirzepatide in MetALD · Phase 2 · recruiting
- NCT07279558 — Cannabidiol and Alcohol Use Disorder Phenotypes · Phase 2 · recruiting
- NCT07056894 — Effects of Action-Based Cognitive Remediation on Substance Misuse in Early Phase Psychosis · NA · recruiting
Other University of Cambridge trials
Trials by the same sponsor.
- NCT07106216 — Evaluating Near-infrared Spectroscopy Devices for Monitoring Traumatic Brain Injury · not yet recruiting
- NCT07154836 — Call for Life: Exploring mHealth Solutions for Enhancing Childhood Vaccinations Among Displaced Children in Conflict-aff · NA · enrolling by invitation
- NCT06844539 — taRgeting bEtA-Cell Function To achIeVe Remission of Type 2 diAbeTEs · NA · recruiting
- NCT07026656 — Pre-clinical Diagnosis Using Integrated Microbial and Host Response Signatures to Improve Outcomes From Ventilator-assoc · recruiting
- NCT06731751 — The Planetary Outcomes After Intracranial Haemorrhage Study · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07341230 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Cambridge
- Last refreshed: 24 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07341230.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing